{"url_path":"/sec/juns/8-k/2026-05-20/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-20","source_url":"https://www.sec.gov/Archives/edgar/data/1679628/0001493152-26-024547-index.html","accession_number":"0001493152-26-024547","cik":"0001679628","ticker":"JUNS","issuer_name":"JUPITER NEUROSCIENCES, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1679628/0001493152-26-024547-index.html","primary_entity_key":"0001679628","primary_entity_name":"JUPITER NEUROSCIENCES, INC."},"word_count":202,"has_tables":true,"body_markdown":"**Item\n7.01 Regulation FD Disclosure.**\n\n \n\nOn\nMay 19, 2026, Jupiter Neurosciences, Inc. (the “**Company**”) and PharmAla Biotech Holdings Inc. (“**PharmAla**”)\nentered into a non-binding summary of proposed terms (the “**Term Sheet**”) regarding a potential licensing transaction\nof PharmAla’s ALA-002 program for the United States. On May 20, 2026, the Company issued a press release announcing the Term Sheet.\nA copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated\nherein by reference.\n\n \n\nThe\ninformation in this Item 7.01, including the press release furnished as an exhibit hereto, is being furnished and shall\nnot be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “**Exchange\nAct**”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing\nunder the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.\nThe Term Sheet is a nonbinding summary of proposed terms and does not create any obligation on the part of the Company or PharmAla to\nconsummate any transaction unless and until definitive agreements are executed."}